Tool overview
Nucleo is listed under Healthcare AI tools.
What is Nucleo?
Nucleo develops AI infrastructure for automated cancer diagnostics. Its medical-imaging workflows process CT scans to quantify body composition and sarcopenia, measure tumor lesions, and classify target versus non-target lesions according to RECIST criteria for oncology and radiology teams.
Best for
Oncology and radiology teams automating quantitative CT review
Who is it for?
Decision note
Confirm regulatory status, intended use, supported scanners and protocols, PACS or workflow integration, validation data, security, data residency, implementation, clinical oversight, support, and current pricing.
Key features
Automated oncology CT image processing
Body-composition and sarcopenia quantification
Tumor-lesion detection and sizing
Target and non-target lesion classification
RECIST-oriented workflow support
Structured imaging data for clinical review
Use cases
Measuring lesions in oncology CT scans
Assessing sarcopenia and body composition
Supporting RECIST response evaluation
Structuring imaging data for cancer care
Pros
- Built specifically for oncology imaging
- Targets repetitive quantitative workflows
- Supports consistent lesion measurements
Cons
- Commercial pricing requires contact
- Clinical validation is site-specific
- Regulatory and diagnostic responsibility remains human
Limitations
Nucleo outputs may miss lesions, misclassify targets, or produce incorrect measurements. Healthcare organizations must validate performance, regulatory status, intended use, privacy, integration, and every clinical result before diagnosis, treatment, or trial decisions.
Pricing details
Billing options
Custom healthcare agreement
Pricing note
Nucleo uses a calendar and contact-form commercial process and does not publish a stable starting price. No ongoing free plan or formal free trial was confirmed. Commercial and clinical scope likely depends on site, imaging volume, integration, validation, regulatory use, and support.
Supported languages
- English
Please log in to join the discussion.